{"id":"https://openalex.org/W4286295205","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691","title":"A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.","display_name":"A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4286295205","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.tps2691","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069346188","display_name":"Adam Sharp","orcid":"https://orcid.org/0000-0002-3740-1612","observed_orcids":["https://orcid.org/0000-0002-3740-1612"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam Sharp","raw_affiliation_strings":["The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom;","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068416680","display_name":"Anja Williams","orcid":"https://orcid.org/0000-0002-4944-1558","observed_orcids":["https://orcid.org/0000-0002-4944-1558"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anja Williams","raw_affiliation_strings":["Sarah Cannon Research Institute UK, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute UK, London, United Kingdom;","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068550336","display_name":"Sarah Patricia Blagden","orcid":"https://orcid.org/0000-0001-8783-3491","observed_orcids":["https://orcid.org/0000-0001-8783-3491"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Patricia Blagden","raw_affiliation_strings":["University of Oxford, Oxford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford, Oxford, United Kingdom;","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033962986","display_name":"Elizabeth Ruth Plummer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elizabeth Ruth Plummer","raw_affiliation_strings":["Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom;","institution_ids":["https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085123244","display_name":"Daniel Hochhauser","orcid":"https://orcid.org/0000-0001-5522-9281","observed_orcids":["https://orcid.org/0000-0001-5522-9281"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Daniel Hochhauser","raw_affiliation_strings":["University College London Cancer Institute, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London Cancer Institute, London, United Kingdom;","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Krebs","raw_affiliation_strings":["Christie NHS Foundation Trust, Manchester, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Christie NHS Foundation Trust, Manchester, United Kingdom;","institution_ids":["https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018384442","display_name":"Simon Pacey","orcid":"https://orcid.org/0000-0002-3303-7577","observed_orcids":["https://orcid.org/0000-0002-3303-7577"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon Pacey","raw_affiliation_strings":["Cambridge Cancer Trials Centre, Cambridge, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cambridge Cancer Trials Centre, Cambridge, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038656790","display_name":"Thomas R. Jeffry Evans","orcid":"https://orcid.org/0000-0002-4175-914X","observed_orcids":["https://orcid.org/0000-0002-4175-914X"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]},{"id":"https://openalex.org/I7882870","display_name":"University of Glasgow","ror":"https://ror.org/00vtgdb53","country_code":"GB","type":"education","lineage":["https://openalex.org/I7882870"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T.R. Jeffry Evans","raw_affiliation_strings":["University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;","institution_ids":["https://openalex.org/I2800373718","https://openalex.org/I7882870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020148707","display_name":"Sarah Whelan","orcid":"https://orcid.org/0000-0003-3468-7405","observed_orcids":["https://orcid.org/0000-0003-3468-7405"]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Whelan","raw_affiliation_strings":["Nurix, San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix, San Francisco, CA;","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012624184","display_name":"Srinand Nandakumar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srinand Nandakumar","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110926892","display_name":"Seema Rogers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seema Rogers","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075204448","display_name":"Katherine LaRoque Jameson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katherine L. Jameson","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103573052","display_name":"Frank G. Basile","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158736","display_name":"Nurix (United States)","ror":"https://ror.org/05k879m03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210158736"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank G. Basile","raw_affiliation_strings":["Nurix Therapeutics, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nurix Therapeutics, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I4210158736"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Johann S. De Bono","raw_affiliation_strings":["The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom;","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012989377","display_name":"Hendrik\u2010Tobias Arkenau","orcid":"https://orcid.org/0000-0002-2015-1549","observed_orcids":["https://orcid.org/0000-0002-2015-1549","https://orcid.org/0000-0003-0372-0540"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Hendrik-Tobias Arkenau","raw_affiliation_strings":["Sarah Cannon Research Institute UK, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute UK, London, United Kingdom;","institution_ids":["https://openalex.org/I172427033"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"TPS2691","last_page":"TPS2691"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/e3-ubiquitin-ligase","display_name":"E3 ubiquitin ligase","score":0.9700000286102295},{"id":"https://openalex.org/keywords/oral-small-molecule-inhibitor","display_name":"oral small-molecule inhibitor","score":0.7409999966621399},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7350000143051147},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7260000109672546},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.8140000104904175},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.7739999890327454},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.6980000138282776},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6949999928474426},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8130000233650208},{"id":"https://openalex.org/keywords/pharmacokinetics-pharmacodynamics","display_name":"pharmacokinetics/pharmacodynamics","score":0.9409999847412109},{"id":"https://openalex.org/keywords/accelerated-titration","display_name":"accelerated titration","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6976503133773804},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6390810012817383},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49993157386779785},{"id":"https://openalex.org/C2776833033","wikidata":"https://www.wikidata.org/wiki/Q1783924","display_name":"Head and neck squamous-cell carcinoma","level":4,"score":0.4383348226547241},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.4113304615020752},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28626179695129395},{"id":"https://openalex.org/C2776530083","wikidata":"https://www.wikidata.org/wiki/Q1783924","display_name":"Head and neck cancer","level":3,"score":0.16908028721809387}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.tps2691","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.tps2691","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/275eb1f9-3623-4ff7-ac00-45a47192e412","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/275eb1f9-3623-4ff7-ac00-45a47192e412","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Sharp, A, Williams, A, Blagden, S, Plummer, E, Hochhauser, D, Krebs, M, Pacey, S, Evans, J, Whelan, S, Nandakumar, S, Rogers, S, Jameson, K, Basile, F, Bono, J & Arkenau, H-T 2022, 'A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.', Journal of Clinical Oncology, vol. 40, pp. TPS2691-TPS2691. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2691","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4416087940","https://openalex.org/W4415941456","https://openalex.org/W4283385015","https://openalex.org/W4389243330","https://openalex.org/W3181836216","https://openalex.org/W4308383762","https://openalex.org/W4410901846","https://openalex.org/W4380080819","https://openalex.org/W7117245533","https://openalex.org/W4413001218"],"abstract_inverted_index":{"TPS2691":[0],"Background:":[1],"Casitas":[2],"B-lineage":[3],"lymphoma":[4,230],"proto-oncogene":[5],"B":[6],"(CBL-B)":[7],"is":[8,58,74,156,238,348,353,367,376,417],"an":[9,75,282],"E3":[10],"ubiquitin":[11],"ligase":[12],"expressed":[13],"in":[14,20,52,90,99,113,118,170,271,307,383,387,402],"multiple":[15],"immune":[16,25,359],"cell":[17,23,36,103,132,184,195],"lineages,":[18],"which":[19],"contrast":[21],"to":[22,46,239,268,273,291,303,379],"surface":[24],"checkpoints,":[26],"acts":[27],"as":[28,93,140],"a":[29,59,95,141,157,171,292,370,391],"regulator":[30],"of":[31,39,80,150,173,186,245,313,317,372],"both":[32,94],"T":[33,54,123],"and":[34,49,63,87,98,116,130,165,189,226,243,249,336,405,407],"NK":[35,131],"activation.":[37],"Inhibition":[38],"CBL-B":[40,57,81],"enhances":[41],"T-cell":[42,70,119,129],"response,":[43],"increases":[44,112],"response":[45,51],"suboptimal":[47],"priming,":[48],"restores":[50],"exhausted":[53],"cells.":[55],"Thus":[56],"promising":[60],"immune-oncology":[61],"target":[62],"may":[64,137,146],"overcome":[65],"challenges":[66],"seen":[67],"with":[68,101,125,231,315,325,341,358,365],"other":[69,151],"directed":[71],"therapies.":[72],"NX-1607":[73,109,136,169,256],"oral":[76],"small":[77],"molecule":[78],"inhibitor":[79],"that":[82,289,330],"has":[83],"demonstrated":[84],"anti-tumor":[85,133,152],"activity":[86],"long-term":[88],"survival":[89],"murine":[91],"models":[92],"single":[96,142],"agent":[97,143],"combination":[100],"programmed":[102],"death":[104],"protein-1":[105],"(PD-1)":[106],"antibodies.":[107],"Further,":[108],"elicits":[110],"dose-dependent":[111],"cytokine":[114],"secretion":[115],"proliferation":[117],"receptor-stimulated":[120],"primary":[121],"human":[122],"cells":[124,364],"enhanced":[126],"tumor":[127],"antigen-specific":[128],"responses.":[134],"Thus,":[135],"be":[138,258,311,396],"effective":[139],"or":[144,214,327,352,362,412],"it":[145],"significantly":[147],"enhance":[148],"efficacy":[149],"agents.":[153],"Methods:":[154],"NX-1607-101":[155],"first-in-human,":[158],"multicenter,":[159],"open-label,":[160],"Phase":[161,253,308,384,388],"1":[162],"dose":[163,275,286],"escalation":[164,278,287,416],"expansion":[166,305],"trial":[167,420],"evaluating":[168],"variety":[172],"indications":[174],"including":[175],"platinum-resistant":[176],"epithelial":[177],"ovarian":[178],"cancer":[179,197,202,210,223],"(EOC),":[180],"gastric":[181],"cancer,":[182,217,219],"squamous":[183],"carcinoma":[185],"the":[187,241,251,403],"head":[188],"neck":[190],"(HNSCC),":[191],"metastatic":[192,199,215,326],"melanoma,":[193],"non-small":[194],"lung":[196],"(NSCLC),":[198],"castration-resistant":[200],"prostate":[201],"(mCRPC),":[203],"malignant":[204],"pleural":[205],"mesothelioma":[206],"(MPM),":[207],"triple-negative":[208],"breast":[209],"(TNBC),":[211],"locally":[212],"advanced":[213,318],"urothelial":[216],"cervical":[218],"microsatellite":[220],"stable":[221],"colorectal":[222],"(MSS":[224],"CRC),":[225],"diffuse":[227],"large":[228],"B-cell":[229],"Richter":[232],"transformation":[233],"(DLBCL-RT).":[234],"The":[235],"main":[236],"objective":[237],"establish":[240],"safety":[242],"tolerability":[244],"NX-1607,":[246],"characterize":[247],"PK/PD,":[248],"determine":[250],"recommended":[252],"1b":[254,309,389],"dose.":[255],"will":[257,279,310,395],"given":[259],"orally":[260],"once":[261],"daily":[262],"at":[263,398],"doses":[264],"ranging":[265],"from":[266],"5":[267],"100":[269],"mg":[270],"up":[272],"6":[274],"levels.":[276],"Dose":[277,415],"proceed":[280],"using":[281,390],"accelerated":[283],"modified":[284],"Fibonacci":[285],"design":[288,297],"transitions":[290],"standard":[293,339],"3":[294,296],"+":[295],"based":[298],"on":[299],"protocol-specific":[300],"criteria.":[301],"Up":[302,378],"8":[304],"cohorts":[306],"composed":[312],"patients":[314,324,381],"subsets":[316],"cancers.":[319],"Key":[320],"eligibility":[321],"criteria":[322],"include":[323],"unresectable":[328],"disease":[329,375,410],"have":[331],"progressed":[332],"after":[333],"prior":[334],"therapy":[335,340],"for":[337],"whom":[338],"proven":[342],"clinical":[343],"benefit":[344],"does":[345],"not":[346,354],"exist,":[347],"no":[349],"longer":[350],"effective,":[351],"appropriate.":[355],"Prior":[356],"treatment":[357],"checkpoint":[360],"inhibitors":[361],"CAR-T":[363],"washout":[366],"allowed,":[368],"but":[369],"history":[371],"active":[373],"autoimmune":[374],"not.":[377],"336":[380],"(60":[382],"1a,":[385],"276":[386],"Simon":[392],"2-stage":[393],"design)":[394],"enrolled":[397],"approximately":[399],"20":[400],"sites":[401],"UK":[404],"US":[406],"treated":[408],"until":[409],"progression":[411],"unacceptable":[413],"toxicity.":[414],"ongoing.":[418],"Clinical":[419],"information:":[421],"NCT05107674.":[422]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-07-21T00:00:00"}